{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_13084", "batch_size": 200, "batch_pos": 169, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment discusses vaccine research history factually.", "method": "llm_batch", "batch_id": "batch_2_14272", "batch_size": 200, "batch_pos": 134, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_11956", "batch_size": 200, "batch_pos": 43, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_18128", "batch_size": 200, "batch_pos": 33, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports history but no explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_9812", "batch_size": 200, "batch_pos": 28, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_10480", "batch_size": 200, "batch_pos": 191, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "No bare negation found.", "method": "llm_batch", "batch_id": "batch_7_20320", "batch_size": 200, "batch_pos": 178, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "no", "rationale": "The segment provides historical context about research, not capabilities or preparedness.", "method": "llm_batch", "batch_id": "batch_8_19696", "batch_size": 200, "batch_pos": 197, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 9, "answer": "no", "rationale": "The segment discusses vaccine research history, not reporting prices or metrics.", "method": "llm_batch", "batch_id": "batch_9_20084", "batch_size": 200, "batch_pos": 150, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 10, "answer": "no", "rationale": "The segment provides historical context about vaccine research, not future relief speculation.", "method": "llm_batch", "batch_id": "batch_10_17044", "batch_size": 179, "batch_pos": 8, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 11, "answer": "no", "rationale": "No direct quote present.", "method": "llm_batch", "batch_id": "batch_11_13820", "batch_size": 177, "batch_pos": 7, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 12, "answer": "yes", "rationale": "No explicit framing cues; factual statement about research history.", "method": "llm_batch", "batch_id": "batch_12_17500", "batch_size": 177, "batch_pos": 7, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
